Male infertility arises from impaired spermatogenesis (low count, motility, or morphology), obstructive azoospermia, ejaculatory dysfunction, or testicular tissue damage — often multifactorial in aetiology. Stem-cell research investigates whether placental mesenchymal stem cells and fetal stem cells can regenerate spermatogenic epithelium, restore Sertoli- and Leydig-cell function, and promote testicular tissue recovery after chemotherapy, trauma, or infection. With 15 registered trials and 3 currently recruiting, the therapeutic scope is narrower than systemic conditions but biologically compelling: testicular microenvironment regeneration could restore fertility. Early preclinical and clinical data suggest potential for improving semen parameters, increasing testosterone production, and potentially recovering spermatogenesis in select azoospermic men.
Male infertility trials are the smallest cohort among studied conditions, reflecting disease prevalence and therapeutic complexity. Three actively recruiting studies indicate emerging clinical interest. Published data predominantly come from small preclinical and early-phase clinical series. Some trials documented improvements in semen parameters (sperm concentration, motility, morphology) following MSC infusion into testicular tissue; a few azoospermic patients recovered some spermatogenesis permitting natural conception or assisted reproduction. Testosterone levels increased in responsive cohorts, suggesting Leydig-cell regeneration. However, study heterogeneity, small sample sizes, and limited controls restrict conclusions. Mechanism studies support germ-cell niche regeneration, but direct in-vivo confirmation in humans remains incomplete. Long-term paternity outcomes are inadequately documented.
Male infertility stem-cell treatment costs typically range €4,000–7,500 per cycle, reflecting the need for testicular biopsy-guided injection or tissue regeneration protocols. Placental MSCs and fetal stem cells incur manufacturing costs; cell dose is often higher than systemic conditions due to target-tissue penetration challenges. Single-infusion protocols predominate, though repeat treatments may be considered 3–6 months after initial therapy if improvement is partial. Sperm cryopreservation and ongoing semen-parameter testing add €500–1,500 to total cost. European andrology centres (Germany, Spain, Italy, Poland) typically charge €4,000–6,000; private boutique fertility clinics may exceed €7,500. Coordination with reproductive medicine may add additional consultation costs.
Cell therapy for Male Infertility is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Male Infertility programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Male Infertility overview · Male Infertility cost →
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita